Evidence map›Paper›PMID 40178605›Full record

ArticleAnnals of hematology2025

Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.

Paul Mobascher, Monika Engelhardt, Ralph Wäsch

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Paul MobascherDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany.
Monika EngelhardtDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany.
Ralph WäschDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany. ralph.waesch@uniklinik-freiburg.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We here report on a patient with relapsed-refractory multiple myeloma (RRMM) who received chimeric antigen receptor (CAR) T-cells (Ciltacabtagene Autoleucel, cilta-cel, Carvykti

Indexed as

Immunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenB-Cell Maturation AntigenHumansRecurrenceB-Cell Maturation AntigenReceptors, Chimeric AntigenCAR T-cellsCilta-celExtramedullary diseaseIde-celMultiple myelomaSequential use

Identifiers

PMID40178605
PMCPMC12031839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.